XOMA Royalty Corporation - Common Stock (XOMA)
Frequently Asked Questions About XOMA Royalty Corporation - Common Stock (XOMA)
Does XOMA develop its own drugs?
No, XOMA does not develop its own drugs. Instead, the company focuses on acquiring royalty interests in drugs developed by other biotechnology and pharmaceutical firms. This allows XOMA to leverage its expertise in managing and monetizing these royalties while minimizing direct development risks.
Does XOMA pay dividends?
As of the latest available information, XOMA does not pay dividends to shareholders. Instead, the company focuses on reinvesting its revenues to support growth and expand its royalty interests.
How can investors stay updated on XOMA’s activities?
Investors can stay updated on XOMA’s activities by following the company’s official website, subscribing to press releases, and reviewing its filings with the Securities and Exchange Commission (SEC). Additionally, participating in quarterly earnings calls can provide insights into the company’s performance and future outlook.
How does XOMA identify potential risks?
XOMA identifies potential risks through comprehensive analysis of its portfolio, market conditions, and the scientific landscape. The company continuously evaluates the performance of its royalty streams and the stability of its partners to mitigate risks.
How does XOMA respond to market changes?
XOMA actively monitors market trends and scientific advancements to adapt its strategies accordingly. The company engages in continuous evaluation of its royalty portfolio to maximize revenue and minimize risks associated with market volatility and competition.
How does XOMA select royalty opportunities?
XOMA employs a rigorous evaluation process to select royalty opportunities, utilizing its expertise in understanding market trends, therapeutic needs, and the scientific validity of the candidates. The company also conducts due diligence to assess the potential for success and revenue generation of the drugs in development.
What are XOMA's long-term goals?
XOMA's long-term goals include expanding its portfolio of royalty interests, enhancing its revenue streams through strategic partnerships, and pursuing new opportunities in high-potential therapeutic areas. The company aims to sustain growth while maintaining a focus on shareholder value.
What are XOMA’s most significant partnerships?
XOMA has established partnerships with a number of leading biotechnology companies, allowing it to diversify its royalty portfolio. Some of the most significant partners include companies engaged in innovative therapeutic development across various fields, including immunology and oncology.
What does XOMA Royalty Corporation do?
XOMA Royalty Corporation is a biotechnology company that specializes in the development of novel therapeutics through a royalty-based business model. It focuses on acquiring, managing, and monetizing royalty interests in companies that are developing advanced therapeutics in various therapeutic areas, including immunology and oncology.
What financial reports does XOMA release to the public?
XOMA regularly releases quarterly and annual financial reports, which provide insights into its financial health, performance metrics, and updates on its royalty agreements. These reports are essential for investors to assess the company's progress and outlook.
What is the primary source of revenue for XOMA?
XOMA's primary source of revenue comes from its royalty agreements with pharmaceutical and biotechnology companies. Specifically, XOMA earns royalties based on sales of innovative therapeutics developed by its partners, which can include both upfront payments and ongoing royalties.
What is the stock symbol for XOMA?
XOMA Royalty Corporation trades on the Nasdaq stock exchange under the stock symbol XOMA. This designation allows investors to easily track and invest in the company's stock.
What is XOMA's financial performance like?
As of its latest financial reports, XOMA has demonstrated a steady financial performance supported by its royalty revenue. Nonetheless, results can fluctuate due to the performance of the underlying drugs within its royalty portfolio and market conditions impacting royalty agreements.
What is XOMA's mission?
XOMA's mission is to maximize shareholder value by strategically acquiring and managing royalty interests in therapeutic products that have the potential to significantly alleviate unmet medical needs. The company aims to leverage its expertise in biotechnology to foster innovation and improve patient outcomes.
What is XOMA’s stance on research and development?
While XOMA does not engage directly in research and development, it heavily relies on the R&D efforts of its partners in the biotechnology industry. The company emphasizes the importance of innovation and scientific advancement in the products generating its royalty income.
What products are included in XOMA’s royalty portfolio?
XOMA's royalty portfolio includes a variety of innovative therapeutic products, particularly in the fields of immunology and oncology. Specific products may vary, as the company updates its portfolio based on acquisitions and developments in its partners' pipelines.
When did XOMA go public?
XOMA Corporation initially went public in 1981. Over the years, the company has undergone various transformations in its business strategy and structure, including its focus on royalties and collaborations in the biotechnology sector.
Where is XOMA Royalty Corporation headquartered?
XOMA Royalty Corporation is headquartered in Berkeley, California. This strategic location places the company in proximity to a vibrant biotechnology and pharmaceutical ecosystem, which facilitates relationships with key industry players.
Who are the key executives at XOMA?
XOMA is led by a team of experienced executives with backgrounds in biotechnology, finance, and corporate development. The leadership team typically includes a CEO, CFO, and other key positions that guide corporate strategy and oversight of operational execution.
What is the current price of XOMA Royalty Corporation - Common Stock?
The current price of XOMA Royalty Corporation - Common Stock is 19.56
When was XOMA Royalty Corporation - Common Stock last traded?
The last trade of XOMA Royalty Corporation - Common Stock was at 2:43 pm EDT on April 4th, 2025
What is the market capitalization of XOMA Royalty Corporation - Common Stock?
The market capitalization of XOMA Royalty Corporation - Common Stock is 230.47M
How many shares of XOMA Royalty Corporation - Common Stock are outstanding?
XOMA Royalty Corporation - Common Stock has 11.78M shares outstanding.